Ann Arbor, MI, United States of America

Lyou-Fu Ma



Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2006-2009

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Lyou-Fu Ma: Innovator in Mental Health Treatments

Introduction

Lyou-Fu Ma is a notable inventor based in Ann Arbor, MI (US), recognized for his contributions to the field of mental health treatments. With a total of two patents to his name, he has made significant strides in addressing social anxiety disorder and obsessive-compulsive disorder through innovative methods.

Latest Patents

One of Lyou-Fu Ma's latest patents focuses on the use of pagoclone for the treatment of social anxiety disorder. This invention provides methods for treating the disorder by administering specific compounds, including 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone or its optical isomers. Additionally, it may involve the administration of another compound that acts as a GABA agonist. Another significant patent involves methods for treating obsessive-compulsive disorder, which includes administering a compound identified as -(-chloro--naphthyridin--yl)--(-methyl--oxo-hexyl)--isoindolinone.

Career Highlights

Throughout his career, Lyou-Fu Ma has worked with prominent companies in the pharmaceutical industry, including Indevus Pharmaceuticals, Inc. and Janssen Pharmaceutica NV. His work has contributed to the development of effective treatments for mental health conditions, showcasing his dedication to improving patient outcomes.

Collaborations

Lyou-Fu Ma has collaborated with esteemed colleagues such as Cathryn M Clary and Jeroen Van Beek, further enhancing the impact of his research and innovations in the field.

Conclusion

Lyou-Fu Ma's innovative work in developing treatments for social anxiety disorder and obsessive-compulsive disorder highlights his significant contributions to mental health. His patents reflect a commitment to advancing therapeutic options for individuals facing these challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…